Anti-CD30 chimeric antigen receptor T cell therapy (Immune cell)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAnti-CD30 chimeric antigen receptor T cell therapy (Immune cell)
Drug Alias NameAnti-CD30 CART cell therapy-Immune CellICAR30 CAR-T cells-Immune CellAnti-CD30 CART cells-Immune cell
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 inhibitors
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsLymphoma, Large-Cell, AnaplasticHodgkin Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesImmune Cell Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmune Cell Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, Large-Cell, AnaplasticHodgkin Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A